Editas Medicine Balance Sheet Health
Financial Health criteria checks 6/6
Editas Medicine has a total shareholder equity of $349.1M and total debt of $0.0, which brings its debt-to-equity ratio to 0%. Its total assets and total liabilities are $499.2M and $150.1M respectively.
Key information
0%
Debt to equity ratio
US$0
Debt
| Interest coverage ratio | n/a |
| Cash | US$323.11m |
| Equity | US$349.10m |
| Total liabilities | US$150.06m |
| Total assets | US$499.15m |
Recent financial health updates
Is Editas Medicine (NASDAQ:EDIT) In A Good Position To Invest In Growth?
Jan 19
We're Hopeful That Editas Medicine (NASDAQ:EDIT) Will Use Its Cash Wisely
Sep 13Is Editas Medicine (NASDAQ:EDIT) In A Good Position To Deliver On Growth Plans?
Jun 12Here's Why We're Not Too Worried About Editas Medicine's (NASDAQ:EDIT) Cash Burn Situation
Nov 17Is Editas Medicine (NASDAQ:EDIT) Using Too Much Debt?
Sep 07Here's Why We're Not Too Worried About Editas Medicine's (NASDAQ:EDIT) Cash Burn Situation
Aug 12Recent updates
The Market Doesn't Like What It Sees From Editas Medicine, Inc.'s (NASDAQ:EDIT) Revenues Yet As Shares Tumble 25%
Apr 23Editas Medicine, Inc. (NASDAQ:EDIT) Surges 28% Yet Its Low P/S Is No Reason For Excitement
Mar 09Editas Medicine: Several Catalysts For Reni-Cel In 2024 Make This A Must Watch
Feb 28New Forecasts: Here's What Analysts Think The Future Holds For Editas Medicine, Inc. (NASDAQ:EDIT)
Dec 15Broker Revenue Forecasts For Editas Medicine, Inc. (NASDAQ:EDIT) Are Surging Higher
May 10Is Editas Medicine (NASDAQ:EDIT) In A Good Position To Invest In Growth?
Jan 19Editas Medicine gains on report of potential sale of pre-clinical cancer pipeline
Oct 18Editas Medicine started at neutral at BofA due to competition in gene editing programs
Sep 29We're Hopeful That Editas Medicine (NASDAQ:EDIT) Will Use Its Cash Wisely
Sep 13Editas: End Of Year Data Readouts For SCD And Rare Eye Disease Studies
Aug 23Editas Medicine Q2 2022 Earnings Preview
Aug 02Baisong Mei joins Editas Medicine as Chief Medical Officer
Jul 18Is Editas Medicine (NASDAQ:EDIT) In A Good Position To Deliver On Growth Plans?
Jun 12Editas: Tackling Rare Eye Disease With Use Of Crispr Technology
Jun 06Editas: The Unforeseen Detrimental Effect Of Patent Win
Mar 25Editas: CRISPR Gene Editing Biotech With Promising Future
Mar 15Analysts' Revenue Estimates For Editas Medicine, Inc. (NASDAQ:EDIT) Are Surging Higher
Feb 25Editas Medicine: A Gene-Editing Company That Has Fallen Significantly In Price Recently
Dec 28Editas - The Introvert Crispr Biotech Too Shy To Flex Its Muscles
Dec 15Here's Why We're Not Too Worried About Editas Medicine's (NASDAQ:EDIT) Cash Burn Situation
Nov 17Editas: Data Was Eagerly Anticipated But Failed To Impress
Nov 03Is Editas Medicine (NASDAQ:EDIT) Using Too Much Debt?
Sep 07Editas: Gene Therapy Specialist Leading The Way In Eye Disease
Aug 27Here's Why We're Not Too Worried About Editas Medicine's (NASDAQ:EDIT) Cash Burn Situation
Aug 12Financial Position Analysis
Short Term Liabilities: EDIT's short term assets ($340.8M) exceed its short term liabilities ($63.2M).
Long Term Liabilities: EDIT's short term assets ($340.8M) exceed its long term liabilities ($86.8M).
Debt to Equity History and Analysis
Debt Level: EDIT is debt free.
Reducing Debt: EDIT had no debt 5 years ago.
Balance Sheet
Cash Runway Analysis
For companies that have on average been loss-making in the past, we assess whether they have at least 1 year of cash runway.
Stable Cash Runway: EDIT has sufficient cash runway for more than a year based on its current free cash flow.
Forecast Cash Runway: EDIT has sufficient cash runway for 1.6 years if free cash flow continues to reduce at historical rates of 19.2% each year.